By Michele Maatouk
Date: Tuesday 18 Aug 2026
(Sharecast News) - Deutsche Bank downgraded Oxford Biomedica to 'hold' from 'buy' on Tuesday and slashed the price target to 595p from 800p as it revisited the investment case following the "disappointing" first-half trading update.
| Total Voting Rights | 02-Jan-2026 | 07:00 | RNS |
| Block Listing Return | 02-Jan-2026 | 07:00 | RNS |
| Should you buy shares in Oxford Biomedica? | 29-Jul-2026 | Times |
| Need to know: Opec cuts forecast ... Tesco cuts ... | 16-Aug-2008 | Times |
| Need to know | 10-May-2008 | Times |
| DSG International may be losing its spark | 12-Feb-2008 | Telegraph |
| Oxford BioMedica clinches $690m licensing deal f... | 29-Mar-2007 | The Independent |
No recent information was found.
| Currency | UK Pounds |
| Share Price | 503.00p |
| Change Today | 11.00p |
| % Change | 2.24 % |
| 52 Week High | 913.00 |
| 52 Week Low | 478.50 |
| Volume | 396,431 |
| Shares Issued | 121.04m |
| Market Cap | £608.85m |
| Beta | 0.03 |
| RiskGrade | 125 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 16:37 | 5,000 @ 503.00p |
| 16:35 | 110,548 @ 503.00p |
| 16:35 | 17 @ 503.00p |
| 16:35 | 777 @ 503.00p |
| 16:35 | 366 @ 503.00p |
| Chair | Roch Doliveux |
| CEO | Frank Mathias |
| CFO | Lucinda (Lucy) Crabtree |
You are here: research